Please check your internet connection and try again.
# Sompraz hp
## Overview
Sompraz hp is a combination product containing esomeprazole, amoxicillin, and clarithromycin. Esomeprazole is a proton pump inhibitor (PPI), while amoxicillin and clarithromycin are antibiotics.
## Primary Indications
* Treatment of *Helicobacter pylori* infection in patients with peptic ulcer disease.
## Adult Dosing
* **Sompraz hp:** One blister pack (containing esomeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg) taken orally twice daily for 7 days.
## Pediatric Dosing
* Information on pediatric dosing for Sompraz hp is not readily available. Dosing for individual components may be used based on age and weight if a combination product is not suitable.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment for esomeprazole is typically required unless severe renal impairment is present. Amoxicillin and clarithromycin doses may require adjustment in moderate to severe renal impairment. Specific guidance should be sought based on individual agent recommendations.
* **Hepatic Impairment:** For esomeprazole, a maximum dose of 20 mg daily is recommended in severe hepatic impairment. Clarithromycin dose reduction is recommended in moderate to severe hepatic impairment. Amoxicillin does not typically require dose adjustment for hepatic impairment.
## Contraindications
* Hypersensitivity to esomeprazole, amoxicillin, clarithromycin, or any other component of the formulation.
* History of allergic reactions to penicillins, cephalosporins, or macrolides.
* Severe hepatic impairment (for clarithromycin).
* Concomitant use with cisapride, ergotamine, lovastatin, simvastatin, or midazolam due to potential for serious adverse events from clarithromycin.
## Adverse Effects
* **Common:** Diarrhea, nausea, abdominal pain, headache, taste disturbance, rash.
* **Serious:** *Clostridioides difficile*-associated diarrhea, Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylaxis, QT prolongation (clarithromycin), hepatic dysfunction, *Clostridium difficile* infection.
## Key Drug Interactions
* **Esomeprazole:** Can decrease the absorption of drugs requiring gastric acidity for absorption (e.g., ketoconazole, itraconazole, iron salts). May increase levels of drugs metabolized by CYP2C19 (e.g., clopidogrel, citalopram).
* **Clarithromycin:** Potent inhibitor of CYP3A4. Numerous interactions are possible, including with statins (lovastatin, simvastatin), ergot alkaloids, cisapride, and certain benzodiazepines. May affect theophylline and carbamazepine levels.
* **Amoxicillin:** May decrease the effectiveness of oral contraceptives. Probenecid can increase and prolong blood levels of amoxicillin.
## Monitoring
* Assess for signs and symptoms of *H. pylori* eradication (e.g., resolution of ulcer symptoms) as appropriate.
* Monitor for signs of hypersensitivity reactions or severe adverse effects, including *C. difficile* infection.
* Monitor hepatic function, especially with prolonged clarithromycin use or in patients with hepatic impairment.
## Clinical Pearls
* This combination therapy is designed to eradicate *H. pylori*. Adherence to the full 7-day course is crucial for treatment success.
* Patients should be advised to take the medication as prescribed and report any new or worsening symptoms immediately.
* The amoxicillin component may be a concern for patients with penicillin allergy.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and your institution's protocols before making any clinical decisions.*
